Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study Comparing i.v. Busulfan (Busilvex) Plus Fludarabine (BuFlu) Versus Busilvex Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age ≥ 40 and =<65 Years) With AML in Complete Remission

Next Previous
Trial Profile

Randomized Study Comparing i.v. Busulfan (Busilvex) Plus Fludarabine (BuFlu) Versus Busilvex Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age ≥ 40 and =<65 Years) With AML in Complete Remission

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Cyclophosphamide
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 13 Dec 2022 Primary endpoint (Transplant-related mortality (TRM)) has been met, as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Results of the long-term analysis comparing busulfan+cyclophosphamide versus busulfan+fludarabine in patients with acute myeloid leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 28 Sep 2015 Results published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top